Nasal drug delivery device

Abstract

The present disclosure relates to a nasal drug delivery device comprising a body assembly, a stem valve, a cap, and an adjustment member. The main body assembly is provided with a containing cavity and a nozzle communicated with the containing cavity; the rod valve is located in the containing cavity and connected with the cavity wall of the containing cavity in a sealed mode. The cover body comprises a shell located outside the main body assembly and a convex column connected to the shell, the convex column is inserted into the containing cavity through the nozzle, a cavity for containing medicine is formed between the convex column and the sealing position of the rod valve, and the convex column is used for limiting the medicine from flowing out of the cavity; the adjusting piece is movably connected to the main body assembly; when the cover body is separated from the main body assembly, and the adjusting part moves in the preset direction, the adjusting part pushes the rod valve to be unsealed from the cavity wall of the containing cavity and compresses gas in the containing cavity to form gas flow flowing towards the nozzle, so that the medicine is sprayed out from the nozzle. According to the nasal medicine delivery device, medicine leakage can be reduced.

Description

Technical Field

[0001] The utility model relates to the technical field of medical devices, in particular to a nasal medicine delivery device. Background Art

[0002] The nasal drug delivery device is used to achieve nasal drug administration, which can be used to treat diseases such as colds, rhinitis, sinusitis, but is not limited to this. Usually, the nasal drug delivery device sprays the drugs placed inside it in the form of mist, and the direction of the spray is toward the nasal cavity. However, there are certain defects in the design of current nasal drug delivery devices, resulting in poor medication effects. For example: the drugs are prone to leakage, resulting in insufficient actual dosage. For example: the drugs cannot be mixed, resulting in the sprayed mist medicine being far from the optimal ratio. The above defects will affect the treatment effect. Utility Model Content

[0003] Problems to be solved by utility models

[0004] In view of at least one of the above technical problems, the present disclosure provides a nasal drug delivery device.

[0005] Solutions for solving problems

[0006] The present disclosure provides a nasal drug delivery device, the nasal drug delivery device comprising:

[0007] A main body component having a receiving cavity and a nozzle connected to the receiving cavity;

[0008] A stem valve is located in the accommodating cavity, and the stem valve is sealedly connected to the cavity wall of the accommodating cavity;

[0009] A cover body, the cover body comprising a shell located outside the main body assembly and a boss connected to the shell, the boss is inserted into the accommodating cavity through the nozzle, a chamber for accommodating medicine is formed between the boss and the sealing position of the stem valve, and the boss is used to limit the medicine from flowing out of the chamber;

[0010] An adjusting member, movably connected to the main body assembly;

[0011] When the cover body is separated from the main body assembly and the adjusting member moves in a preset direction, the adjusting member pushes the stem valve to release the seal from the cavity wall of the accommodating cavity, and compresses the gas in the accommodating cavity to form an airflow flowing toward the nozzle, so that the medicine is ejected from the nozzle.

[0012] Optionally, the main body component includes:

[0013] a first hollow member having the nozzle;

[0014] The second hollow member is located in the first hollow member, and the two ends of the second hollow member respectively have a first opening and a second opening connected to the accommodating cavity, the first opening is located between the nozzle and the second opening, and the stem valve is sealed and connected to the second hollow member.

[0015] Optionally, the inner wall of the second hollow member has a first boss protruding radially inward;

[0016] The stem valve has a second boss protruding radially outward, and the second boss abuts against the first boss to limit the stem valve from moving in a direction opposite to the preset direction.

[0017] Optionally, the protrusion abuts against the second hollow part to restrict the medicine from flowing out of the second hollow part; or,

[0018] The nasal drug delivery device also includes: an air-blocking valve, which is at least partially inserted into the second hollow part through the first opening to limit the drug from flowing out of the second hollow part; the protrusion abuts against the air-blocking valve to limit the separation of the air-blocking valve from the second hollow part.

[0019] Optionally, the nasal drug delivery device has a spiral channel in the flow path of the drug sprayed out of the accommodating cavity through the nozzle.

[0020] Optionally, the spiral channel is formed on the inner wall of the accommodating cavity; and / or, the spiral channel is formed on the outer wall of the air-blocking valve.

[0021] Optionally, the air-blocking valve comprises:

[0022] a valve body, at least partially located within the second hollow member;

[0023] A valve flange protrudes radially outward from the valve body, and the valve flange abuts against the second hollow member to limit the air resistance valve from moving in a direction opposite to the preset direction.

[0024] Optionally, the main body component further has a mounting port communicating with the accommodating cavity, and the mounting port and the nozzle are respectively located on opposite sides of the main body component;

[0025] The adjusting member covers the installation opening and is partially inserted into the accommodating cavity from the installation opening; the volume of the adjusting member inserted into the accommodating cavity when the adjusting member is subjected to external force is greater than the volume of the adjusting member inserted into the accommodating cavity when the adjusting member is not subjected to external force.

[0026] Optionally, the first hollow member comprises:

[0027] A first side wall extending in the axial direction, formed as a part of the accommodating cavity;

[0028] A second side wall extending in the axial direction is formed with the nozzle and is used to penetrate deep into the nasal cavity;

[0029] A shoulder extending in a radial direction, extending radially outward from the second side wall along the first hollow member to the first side wall;

[0030] An extension wall extending along the axis is located inside the accommodating cavity and extends from the shoulder to the second side wall. The second hollow part is located in a space formed by the extension wall and the first side wall.

[0031] Optionally, the second side wall is located between the boss and the housing.

[0032] Effect of utility model

[0033] In the disclosed embodiment, since the convex column of the cover body is inserted into the accommodating cavity through the nozzle, the convex column can be used to strengthen the sealing of the cavity, thereby reducing the leakage of drugs outside the cavity due to vibrations generated during transportation or use. When using the nasal drug delivery device to administer drugs, the cover body can be removed, the nozzle can be aimed at the nasal cavity, and the adjustment member can be moved in a preset direction to compress the gas in the accommodating cavity to form an airflow rushing toward the cavity, and the airflow will spray the drugs into a mist. In addition, the outer shell of the cover body can also reduce the exposure of the main component to the external environment, thereby reducing the contamination of the part of the main component entering the nasal cavity. BRIEF DESCRIPTION OF THE DRAWINGS

[0034] Figure 1 This is an appearance diagram of a nasal drug delivery device before use in an optional embodiment of the present disclosure;

[0035] Figure 2 for Figure 1 A longitudinal cross-sectional view of a mid-nasal drug delivery device;

[0036] Figure 3 for Figure 1 A schematic diagram of the structure of the nasal drug delivery device in use;

[0037] Figure 4 for Figure 3 A longitudinal cross-sectional view of a mid-nasal drug delivery device;

[0038] Figure 5 for Figure 1 Schematic diagram of the structure of the middle air-blocking valve;

[0039] Figure 6 Different from Figure 1 Cross-sectional view of a nasal drug delivery device of the illustrated embodiment.

[0040] Description of Reference Numerals

[0041] 100, nasal drug delivery device; 101, receiving chamber; 102, nozzle; 103, mounting port; 104, chamber; 110, main body assembly; 110a, first side wall; 110b, second side wall; 110c, shoulder; 110d, extension wall; 111, first hollow member; 112, second hollow member; 112a, second opening; 112b, first boss; 121, second Boss; 120, stem valve; 130, cover body; 131, outer shell; 132, boss; 140, adjusting member; 141, inner sleeve; 141a, side wall of inner sleeve; 141b, bottom wall of inner sleeve; 141c, outer edge; 142, first outer sleeve; 150, air-blocking valve; 150a, spiral channel; 151, valve body; 152, valve flange; 160, second outer sleeve; 161, curling portion. DETAILED DESCRIPTION

[0042] In order to make the technical solutions and beneficial effects of the embodiments of the present disclosure more obvious and easy to understand, the following is a detailed description by listing specific embodiments. The drawings are not necessarily drawn to scale, and local features may be enlarged or reduced to more clearly show the details of the local features; unless otherwise defined, the technical and scientific terms used herein have the same meaning as those in the technical field to which this application belongs.

[0043] In the description of the embodiments of the present disclosure, terms such as "center", "longitudinal", "lateral", "length", "width", "thickness", "height", "up", "down", "front", "back", "left", "right", "vertical", "horizontal", "top", "bottom", "inside", "outside", "clockwise", "counterclockwise", etc. indicate orientations or positional relationships based on the orientations or positional relationships shown in the accompanying drawings, and are only for the convenience of simplified description of the embodiments of the present disclosure, and do not indicate that the referred device or element must have a specific orientation, be constructed and operated in a specific orientation, and should not be understood as a limitation on the embodiments of the present disclosure.

[0044] In the embodiments of the present disclosure, the terms "first" and "second" are only used for the purpose of clear description and cannot be understood as the relative importance of the indicated features or the number of the indicated technical features. Therefore, the features defined as "first" and "second" can explicitly include at least one of the features. In the description of the embodiments of the present disclosure, the meaning of "multiple" is at least two, such as two, three, etc.; the meaning of "several" is at least one, such as one, two, three, etc., unless otherwise clearly and specifically defined.

[0045] In the embodiments of the present disclosure, unless otherwise clearly defined, the terms "installed", "connected", "connected", "fixed", "set", etc. should be understood in a broad sense. For example, "connection" can be a fixed connection, a detachable connection, or an integral connection; it can be a mechanical connection or an electrical connection; it can be a direct connection, or an indirect connection through an intermediate medium, or it can be the internal connection of two elements or the interaction relationship between two elements. For ordinary technicians in this field, the specific meanings of the above terms in the embodiments of the present disclosure can be understood according to the specific circumstances.

[0046] In the embodiments of the present disclosure, unless otherwise clearly defined, a first feature being “on”, “above”, “above”, “below”, “below”, “below” or “below” a second feature may mean that the first feature is in direct contact with the second feature, or the first feature and the second feature are in indirect contact with each other through an intermediate medium. Moreover, a first feature being “on”, “above” or “above” a second feature may mean that the first feature is directly above or obliquely above the second feature, or simply means that the horizontal height of the first feature is higher than the horizontal height of the second feature. A first feature being “below”, “below” or “below” a second feature may mean that the first feature is directly below or obliquely below the second feature, or simply means that the horizontal height of the first feature is less than the horizontal height of the second feature.

[0047] The nasal drug delivery device of the present disclosure includes: Figure 1 and Figure 2 The state before use shown, and Figure 3 and Figure 4 The in-use state is shown. Before use, the medicine can be pre-filled in the containing cavity.

[0048] Medicines include, but are not limited to, solid medicines, semi-solid medicines or liquid medicines. Solid medicines are generally in powder or granular form.

[0049] like Figures 1 to 4 ,as well as Figure 6 As shown, the embodiment of the present disclosure provides a nasal drug delivery device 100, which includes: a main body component 110, a stem valve 120, a cover body 130 and an adjusting member 140; wherein the main body component 110 has a receiving chamber 101, and a nozzle 102 connected to the receiving chamber 101. The stem valve 120 is located in the receiving chamber 101, the cover body 130 includes a substantially cylindrical shell 131 and a convex column 132 located in the shell 131, the convex column 132 extends from the top wall of the shell 131 along the axial direction of the shell 131, and the adjusting member 140 is movably connected to the main body component 110.

[0050] When the nasal drug delivery device 100 is in a state before use, the housing 131 is sleeved outside the main assembly 110, the protruding column 132 is inserted into the accommodating chamber 101 from the nozzle 102, and there is a gap between the stem valve 120 and the regulating member 140. The stem valve 120 is sealed and connected to the cavity wall of the accommodating chamber 101, and a chamber 104 for accommodating drugs is formed between the sealing position of the protruding column 132 and the stem valve 120, wherein the protruding column 132 can help seal the chamber 104, and is used to limit the flow of drugs out of the chamber 104.

[0051] like Figure 2 and Figure 6 As shown, the size of the portion of the boss 132 inserted into the nozzle 102 can match the size of the nozzle 102, so that the boss 132 can block and close the nozzle 102, or, in some embodiments not shown in the present disclosure, the size of the boss 132 inserted into the nozzle 102 can be smaller than the size of the nozzle 102, and the boss 132 does not play a sealing role on the nozzle 102, and the nozzle 102 is closed by the external shell 131.

[0052] exist Figures 1 to 4 In the illustrated embodiment, the protrusion 132 indirectly seals the chamber 104. For example, the nasal drug delivery device 100 further includes an air-blocking valve 150, the lower portion of the chamber 104 is sealed by the sealing position of the stem valve 120, and the upper opening of the chamber 104 is blocked and sealed by the air-blocking valve 150. The protrusion 132 can press the air-blocking valve 150 to reduce the movement of the air-blocking valve 150 caused by shaking, vibration or inversion, thereby ensuring the air-blocking valve 150's sealing effect on the chamber 104.

[0053] exist Figure 6 In the embodiment shown, the protruding column 132 can directly seal the chamber 104. In this case, the air blocking valve 150 can be eliminated, and the upper opening of the chamber 104 can be directly sealed by the protruding column 132, and the cover 130 and the main body assembly 110 are fixed by the cooperation of the housing and the main body assembly 110, thereby ensuring the sealing effect of the protruding column 132 on the chamber 104, and the medicine in the chamber 104 cannot leak even if it is shaken, vibrated or inverted.

[0054] When the nasal drug delivery device 100 is needed, the cover 130 is removed, and the main component 110 has a partial structure of the nozzle 102 that can be extended into the nasal cavity. An external force in a preset direction is applied to the adjustment component, and the adjustment member 140 moves in the preset direction. During the movement of the adjustment component, the adjustment member 140 contacts the lower end of the stem valve 120, and the adjustment member 140 pushes the stem valve 120 to release the seal with the cavity wall of the accommodating cavity 101, and compresses the gas in the accommodating cavity 101 to form an airflow flowing toward the nozzle 102, so that the drug is ejected from the nozzle 102.

[0055] Exemplarily, the engagement between the housing and the main assembly 110 may be at least one of friction engagement, snap engagement, or thread engagement.

[0056] Optionally, refer to Figures 1 to 4 as well as Figure 6 As shown, the preset direction is the direction along the axial direction of the nasal drug delivery device 100 toward the nozzle 102, that is, the upward direction.

[0057] In the disclosed embodiment, since the protrusion 132 of the cover 130 is inserted into the accommodating chamber 101 through the nozzle 102, the protrusion 132 can be used to strengthen the sealing of the chamber 104, thereby reducing the leakage of the drug outside the chamber 104 caused by the vibration generated during transportation or use. When using the nasal drug delivery device 100 to administer drugs, the cover 130 can be removed, the nozzle 102 is aimed at the nasal cavity, and the adjustment member 140 is moved in a preset direction to compress the gas in the accommodating chamber 101 to form an airflow rushing toward the chamber 104, and the airflow sprays the drug into a mist. In addition, the shell 131 of the cover 130 can also reduce the exposure of the main component 110 to the external environment, thereby reducing the contamination of the part of the main component 110 entering the nasal cavity.

[0058] exist Figures 1 to 4 In the illustrated embodiment, when the nasal drug delivery device 100 is in use, the generated airflow can lift the air barrier valve 150 , and the fluid can flow toward the nozzle 102 through the gap between the air barrier valve 150 and the inner wall of the chamber 104 .

[0059] The sealing position of the stem valve 120 refers to the sealing position between the stem valve 120 and the inner wall of the chamber 104. For example, the two can be interference-fitted at this position to achieve sealing.

[0060] The portion of the accommodating cavity 101 between the sealing position of the stem valve 120 and the connection position of the adjusting member 140 and the main assembly 110, that is, Figure 2 The volume of the lower part of the accommodating chamber 101 determines the fluid pressure of the spray. Generally, the larger the volume of the accommodating chamber 101, the greater the amount of air compressed by the adjusting member 140, and the greater the fluid pressure formed. Vice versa.

[0061] like Figure 2 and Figure 4 As shown, according to some optional embodiments, the main body component 110 includes: a first hollow part 111 and a second hollow part 112, the first hollow part 111 having a nozzle 102; the second hollow part 112 is located in the first hollow part 111, and the two ends of the second hollow part 112 respectively have a first opening and a second opening 112a connected to the accommodating cavity 101, the first opening is located between the nozzle 102 and the second opening 112a, and the stem valve 120 is sealed and connected to the second hollow part 112.

[0062] The second hollow part 112 is located inside the first hollow part 111, and the two ends of the second hollow part 112 are spaced from the two ends of the first hollow part 111 by a certain distance. The second hollow part 112 and the second hollow part 112 are roughly coaxially distributed, and the chamber 104 containing the medicine is located in the second hollow cavity. The stem valve 120 is sealed and connected to the inner wall of the part of the second hollow part 112 adjacent to the second opening 112a. After the part of the accommodating cavity 101 below the second hollow part 112 is compressed by the regulating part 140, the generated airflow passes through the second opening 112a, the space between the second hollow part 112 and the stem valve 120, and the first opening in sequence, and finally is ejected from the nozzle 102.

[0063] If the nasal drug delivery device 100 is provided with an air blocking valve 150, the air blocking valve 150 blocks the first opening. Figure 2 As shown, the air-blocking valve 150 is at least partially inserted into the second hollow member 112 through the first opening to restrict the drug from flowing out of the second hollow member 112 ; the protruding column 132 abuts against the air-blocking valve 150 to restrict the air-blocking valve 150 from separating from the second hollow member 112 .

[0064] If the nasal drug delivery device 100 does not have an air barrier valve 150, such as Figure 6 As shown, according to some optional embodiments, the protruding column 132 abuts against the second hollow member 112 to restrict the drug from flowing out of the second hollow member 112 .

[0065] Optionally, in order to ensure the flow rate of the mist fluid sprayed from the chamber 104, the structure of the second hollow member 112 at the first outlet can be adaptively improved. Exemplarily, the first outlet can be an outlet that tapers upward, or the second hollow member 112 further has a top wall opposite to the nozzle 102, and the second outlet can be a smaller outlet located on the top wall or side wall of the second hollow member 112, or the first outlet can be formed into a narrow and long outlet by other means.

[0066] like Figure 2 and Figure 4 As shown, according to some optional embodiments, the inner wall of the second hollow member 112 has a first boss 112b protruding radially inward; the stem valve 120 has a second boss 121 protruding radially outward, and the second boss 121 abuts against the first boss 112b, so that the stem valve 120 can only move in a preset direction after being subjected to an external force, and the movement of the stem valve 120 in a direction opposite to the preset direction is restricted by the first boss 112b.

[0067] According to some optional embodiments, the nasal drug delivery device 100 has a spiral channel 150 a in the flow path of the drug sprayed out of the accommodating cavity 101 through the nozzle 102 .

[0068] In some usage scenarios, the medicines pre-filled in the chamber 104 may be two or more kinds, which are pre-filled in the chamber 104 in an optimal ratio, and the two or more kinds of medicines cannot be pre-mixed, and each medicine must be pre-stored separately in the chamber 104. When taking the medicine, it is necessary to mix it evenly as soon as possible before entering the nasal cavity.

[0069] There are also some usage scenarios where the drug needs to be diluted or moistened before administration, that is, the drug is in liquid or semi-solid state when administered. In this case, in addition to the solid drug, liquid diluent is also required to be pre-filled in the chamber 104, and the two are stored in the chamber 104 in the best ratio and separated in the chamber 104. After the adjustment member 140 is activated, the drug and the diluent need to be mixed evenly.

[0070] By providing the spiral channel 150a, the mixing requirements of the medicines in the above two usage scenarios can be met. The spiral channel 150a helps to disturb the fluid, for example, to form a vortex in the fluid, so as to improve the mixing uniformity of at least two medicines in the fluid, or to improve the mixing uniformity of the medicine and the diluent, so that the mixed medicine sprayed into the nasal cavity can be closer to the optimal ratio, thereby improving the treatment effect.

[0071] Figure 5 The spiral channel 150a is exemplarily shown to be formed on the outer wall of the air-blocking valve 150. After the stem valve 120 pushes the air-blocking valve 150 away from the second hollow member 112, the fluid containing the medicine can be sprayed upward along the spiral channel 150a on the outer wall of the air-blocking valve 150 through the first opening.

[0072] If the nasal drug delivery device 100 does not have the air blocking valve 150 , the spiral channel 150 a can be formed on the inner wall of the accommodating chamber 101 adjacent to the nozzle 102 . For example, the spiral channel 150 a is provided on the inner wall of the accommodating chamber 101 between the second hollow member 112 and the nozzle 102 .

[0073] In some optional embodiments, the spiral channel 150 a may be formed on the inner wall of the accommodating chamber 101 adjacent to the nozzle 102 and the outer wall of the air resistance valve 150 .

[0074] like Figure 5 As shown, according to some optional embodiments, the air-blocking valve 150 includes: a valve body 151 and a valve flange 152, the valve body 151 is at least partially located in the second hollow part 112; the valve flange 152 protrudes radially outward from the valve body 151, and the valve flange 152 abuts against the second hollow part 112, so that the air-blocking valve 150 can only move in a preset direction, and the movement in the direction opposite to the preset direction is restricted.

[0075] like Figure 2 and Figure 4As shown, according to some optional embodiments, the main body component 110 also has a mounting port 103 connected to the accommodating cavity 101, and the mounting port 103 and the nozzle 102 are respectively located on opposite sides of the main body component 110; the adjusting member 140 covers the mounting port 103 and is partially inserted into the accommodating cavity 101 from the mounting port 103; the volume of the adjusting member 140 inserted into the accommodating cavity 101 when subjected to external force is greater than the volume of the adjusting member 140 inserted into the accommodating cavity 101 when not subjected to external force.

[0076] The adjusting member 140 can not only seal the installation opening 103 of the main assembly 110, but also move relative to the main assembly 110 in a preset direction with the aid of the installation opening 103. Figure 1 As shown, when the nasal drug delivery device 100 is in a state before use, the adjusting member 140 protrudes more from the main component 110; Figure 3 As shown in FIG. 1 , when the nasal drug delivery device 100 is in use, the portion of the finger adjustment member 140 protruding outside the main assembly 110 is small. Figure 2 and Figure 4 As shown, the regulating member 140 includes: an inner sleeve 141 and a first outer sleeve 142. The inner sleeve 141 includes a bottom wall 141b and a side wall 141a extending axially along the bottom wall 141b toward the opening direction. The side wall 141a is arranged to form an opening. The outer peripheral surface of the side wall 141a has an outer edge 141c protruding radially outward. The outer edge 141c abuts against the side wall of the accommodating chamber 101. The bottom wall 141b of the inner sleeve 141 covers the installation opening 103, so that the installation opening 103 can be closed. The first outer sleeve 142 is located outside the inner sleeve 141, and is used to transmit the received external force to the inner sleeve 141 and drive the inner sleeve 141 to move. When the bottom wall 141b of the inner sleeve 141 contacts the bottom end of the stem valve 120, the inner sleeve 141 continues to move, and the inner sleeve 141 can push the stem valve 120 to move until the spraying is completed.

[0077] It is understandable that the first outer sleeve 142 may be omitted and spraying may still be achieved by retaining the inner sleeve 141 .

[0078] like Figures 1 to 4 As shown, the nasal drug delivery device 100 further includes a second outer sleeve 160 located outside the lower portion of the main assembly 110. The second outer sleeve 160 is substantially cylindrical and has openings at both ends. Figure 4 As shown, the side wall of the second outer sleeve 160 has an inwardly facing curled edge portion 161, and the curled edge portion 161 surrounds the mounting opening 103. When the nasal drug delivery device 100 is in a state before use, the curled edge portion 161 can abut against the adjusting member 140, so that the adjusting member 140 cannot move in a direction opposite to the preset direction, thereby limiting the separation of the adjusting member 140 from the main body assembly 110 and ensuring the reliability of the connection between the adjusting member 140 and the main body assembly 110.

[0079] Depend on Figure 2 and Figure 4 It can be seen that the first outer cover 142 and the second outer cover 160 can be used as the outer shell of the nasal drug delivery device 100, and have a certain protective effect on the main body component 110 and the inner cover 141 therein.

[0080] like Figure 2 , Figure 4 and Figure 6 As shown, according to some optional embodiments, the first hollow member 111 includes: a first side wall 110a extending axially, a second side wall 110b extending axially, a shoulder 110c extending radially, and an extension wall 110d extending along the axis, the first side wall 110a is formed as a part of the accommodating cavity 101; the second side wall 110b is formed with a nozzle 102 and is used to penetrate into the nasal cavity; the shoulder 110c extends radially outward from the second side wall 110b along the first hollow member 111 to the first side wall 110a; the extension wall 110d is located inside the accommodating cavity 101, and extends from the shoulder 110c to the second side wall 110b, and the second hollow member 112 is located in the space formed by the extension wall 110d and the first side wall 110a.

[0081] The length of the second side wall 110b can be adjusted according to the depth of the nasal cavity. When the nasal drug delivery device 100 is in use, at least a portion of the second side wall 110b can be inserted deep into the nasal cavity so that the spray can more easily reach a designated position in the nasal cavity.

[0082] like Figure 2 and Figure 6 As shown, according to some optional embodiments, the second side wall 110b is located between the protrusion 132 and the housing 131. The second side wall 110b can be surrounded by the housing 131, reducing the exposure of the second side wall 110b to the external environment, thereby reducing the pollution of the second side wall 110b.

[0083] Under the premise of no conflict, different embodiments or different technical features of the present disclosure can be arbitrarily combined to form new embodiments.

[0084] It should be understood that the above embodiments are exemplary and are not intended to include all possible implementations included in the claims. Various modifications and changes may be made on the basis of the above embodiments without departing from the scope of the present disclosure. Similarly, the various technical features of the above embodiments may be arbitrarily combined to form other embodiments of the present invention that may not be explicitly described. Therefore, the above embodiments only express several implementations of the present invention and do not limit the scope of protection of the patent of the present invention.

Claims

1. A nasal drug delivery device, characterized in that: The nasal drug delivery device comprises: A main body component having a receiving cavity and a nozzle connected to the receiving cavity; A stem valve is located in the accommodating cavity, and the stem valve is sealed and connected to the cavity wall of the accommodating cavity; A cover body, the cover body comprising a shell located outside the main body assembly and a boss connected to the shell, the boss is inserted into the accommodating cavity through the nozzle, a chamber for accommodating medicine is formed between the boss and the sealing position of the stem valve, and the boss is used to limit the medicine from flowing out of the chamber; An adjusting member, movably connected to the main body assembly; When the cover body is separated from the main body assembly and the adjusting member moves in a preset direction, the adjusting member pushes the stem valve to release the seal from the cavity wall of the accommodating cavity, and compresses the gas in the accommodating cavity to form an airflow flowing toward the nozzle, so that the medicine is ejected from the nozzle.

2. The nasal drug delivery device according to claim 1, characterized in that The main body component comprises: a first hollow member having the nozzle; The second hollow member is located in the first hollow member, and the two ends of the second hollow member respectively have a first opening and a second opening connected to the accommodating cavity, the first opening is located between the nozzle and the second opening, and the stem valve is sealed and connected to the second hollow member.

3. The nasal drug delivery device according to claim 2, characterized in that The inner wall of the second hollow member has a first boss protruding radially inward; The stem valve has a second boss protruding radially outward, and the second boss abuts against the first boss to limit the stem valve from moving in a direction opposite to the preset direction.

4. The nasal drug delivery device according to claim 2, characterized in that: The protruding column abuts against the second hollow part to restrict the medicine from flowing out of the second hollow part; or, The nasal drug delivery device also includes: an air-blocking valve, which is at least partially inserted into the second hollow part through the first opening to limit the drug from flowing out of the second hollow part; the protrusion abuts against the air-blocking valve to limit the separation of the air-blocking valve from the second hollow part.

5. The nasal drug delivery device according to claim 4, characterized in that The nasal medicine delivery device has a spiral channel in the flow path of the medicine sprayed out of the accommodating cavity through the nozzle.

6. The nasal drug delivery device according to claim 5, characterized in that The spiral channel is formed on the inner wall of the accommodating cavity; and / or, the spiral channel is formed on the outer wall of the air-blocking valve.

7. The nasal drug delivery device according to claim 5, characterized in that The air blocking valve comprises: a valve body, at least partially located within the second hollow member; A valve flange protrudes radially outward from the valve body, and the valve flange abuts against the second hollow member to limit the air resistance valve from moving in a direction opposite to the preset direction.

8. The nasal drug delivery device according to any one of claims 1 to 7, characterized in that: The main body component also has a mounting port communicating with the accommodating cavity, and the mounting port and the nozzle are respectively located on opposite sides of the main body component; The adjusting member covers the installation opening and is partially inserted into the accommodating cavity from the installation opening; the volume of the adjusting member inserted into the accommodating cavity when the adjusting member is subjected to external force is greater than the volume of the adjusting member inserted into the accommodating cavity when the adjusting member is not subjected to external force.

9. The nasal drug delivery device according to claim 2, characterized in that: The first hollow member comprises: A first side wall extending in the axial direction, formed as a part of the accommodating cavity; A second side wall extending in the axial direction is formed with the nozzle and is used to penetrate deep into the nasal cavity; A shoulder extending in a radial direction, extending radially outward from the second side wall along the first hollow member to the first side wall; An extension wall extending along the axis is located inside the accommodating cavity and extends from the shoulder to the second side wall. The second hollow part is located in a space formed by the extension wall and the first side wall.

10. The nasal drug delivery device according to claim 9, characterized in that The second side wall is located between the boss and the housing.

Images